Yasong Lu

931 total citations
19 papers, 310 citations indexed

About

Yasong Lu is a scholar working on Oncology, Pharmacology and Pharmacology. According to data from OpenAlex, Yasong Lu has authored 19 papers receiving a total of 310 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Pharmacology and 5 papers in Pharmacology. Recurrent topics in Yasong Lu's work include Drug Transport and Resistance Mechanisms (6 papers), Alzheimer's disease research and treatments (4 papers) and Computational Drug Discovery Methods (4 papers). Yasong Lu is often cited by papers focused on Drug Transport and Resistance Mechanisms (6 papers), Alzheimer's disease research and treatments (4 papers) and Computational Drug Discovery Methods (4 papers). Yasong Lu collaborates with scholars based in United States, China and Switzerland. Yasong Lu's co-authors include Meicun Yao, Manupat Lohitnavy, Raymond S. H. Yang, Jingwen Gao, Ornrat Lohitnavy, Ping Huang, Shyeilla V. Dhuria, Arnaud Grandeury, Felix Huth and Kenichi Umehara and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, Journal of Ethnopharmacology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Yasong Lu

19 papers receiving 305 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yasong Lu United States 12 102 76 63 57 54 19 310
Paola Puccini Italy 14 104 1.0× 59 0.8× 68 1.1× 138 2.4× 72 1.3× 46 495
Yaomin Du China 8 56 0.5× 64 0.8× 34 0.5× 133 2.3× 79 1.5× 8 421
Yukiyoshi Fujita Japan 10 82 0.8× 38 0.5× 61 1.0× 78 1.4× 78 1.4× 39 358
Hannah Lu United States 8 75 0.7× 37 0.5× 24 0.4× 62 1.1× 88 1.6× 9 441
Kirk Bertelsen United States 8 126 1.2× 58 0.8× 24 0.4× 53 0.9× 188 3.5× 11 456
Tsu‐Han Lin United States 13 130 1.3× 43 0.6× 22 0.3× 149 2.6× 75 1.4× 20 751
Lisette Binkhorst Netherlands 11 106 1.0× 69 0.9× 14 0.2× 59 1.0× 162 3.0× 14 365
Sheng Ma China 9 78 0.8× 47 0.6× 11 0.2× 161 2.8× 43 0.8× 41 422
E Péquignot United States 10 66 0.6× 31 0.4× 85 1.3× 69 1.2× 76 1.4× 19 393

Countries citing papers authored by Yasong Lu

Since Specialization
Citations

This map shows the geographic impact of Yasong Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasong Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasong Lu more than expected).

Fields of papers citing papers by Yasong Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yasong Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasong Lu. The network helps show where Yasong Lu may publish in the future.

Co-authorship network of co-authors of Yasong Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Yasong Lu. A scholar is included among the top collaborators of Yasong Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yasong Lu. Yasong Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Lu, Yasong, et al.. (2021). Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients. The Journal of Clinical Pharmacology. 61(8). 1054–1068. 15 indexed citations
2.
Samant, Tanay S., Shyeilla V. Dhuria, Yasong Lu, et al.. (2017). Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations. Clinical Pharmacology & Therapeutics. 104(2). 374–383. 64 indexed citations
3.
Lohitnavy, Manupat, Yasong Lu, Ornrat Lohitnavy, & Raymond S. H. Yang. (2017). A physiologically-based pharmacokinetic model of methotrexate incorporating hepatic excretion via multidrug-resistance-associated protein 2 (Mrp2) in mice, rats, dogs, and humans. PubMed. 2017. 2728–2731. 4 indexed citations
4.
Bell, J. Simon, Brian T. O’Neill, Michael A. Brodney, et al.. (2013). P1–351: A novel BACE inhibitor (PF‐05297909): A two‐part adaptive design to evaluate safety, pharmacokinetics and pharmacodynamics for modifying beta‐amyloid in a first‐in‐human study. Alzheimer s & Dementia. 9(4S_Part_7). 7 indexed citations
5.
Feng, Bo, Susan Hurst, Yasong Lu, et al.. (2013). Quantitative Prediction of Renal Transporter-Mediated Clinical Drug–Drug Interactions. Molecular Pharmaceutics. 10(11). 4207–4215. 29 indexed citations
6.
Gao, Jingwen, Zhan Shi, Ping Huang, et al.. (2012). Herb–drug pharmacokinetic interaction between radix astragali and pioglitazone in rats. Journal of Ethnopharmacology. 144(2). 300–304. 15 indexed citations
7.
8.
Lu, Yasong, Hugh A. Barton, Louis Leung, et al.. (2012). Cerebrospinal Fluid β-Amyloid Turnover in the Mouse, Dog, Monkey and Human Evaluated by Systematic Quantitative Analyses. Neurodegenerative Diseases. 12(1). 36–50. 18 indexed citations
9.
Lu, Yasong, David Riddell, Éva Hajós‐Korcsok, et al.. (2012). Cerebrospinal Fluid Amyloid-β (Aβ) as an Effect Biomarker for Brain Aβ Lowering Verified by Quantitative Preclinical Analyses. Journal of Pharmacology and Experimental Therapeutics. 342(2). 366–375. 24 indexed citations
10.
11.
Lu, Yasong, Hugh A. Barton, Timothy Nicholas, et al.. (2012). P1‐296: An updated Aβ systems kinetic model for mouse, monkey and human. Alzheimer s & Dementia. 8(4S_Part_6). 1 indexed citations
12.
Gao, Jingwen, et al.. (2012). Development of a rapid UPLC‐MS/MS method for quantification of saxagliptin in rat plasma and application to pharmacokinetic study. Biomedical Chromatography. 26(12). 1482–1487. 19 indexed citations
13.
Lu, Yasong, Liming Zhang, Charles E. Nolan, et al.. (2011). Quantitative Pharmacokinetic/Pharmacodynamic Analyses Suggest That the 129/SVE Mouse Is a Suitable Preclinical Pharmacology Model for Identifying Small-Molecule γ-Secretase Inhibitors. Journal of Pharmacology and Experimental Therapeutics. 339(3). 922–934. 19 indexed citations
14.
15.
Lu, Yasong, Susan Rieth, Manupat Lohitnavy, et al.. (2008). Application of PBPK modeling in support of the derivation of toxicity reference values for 1,1,1-trichloroethane. Regulatory Toxicology and Pharmacology. 50(2). 249–260. 18 indexed citations
16.
Lohitnavy, Manupat, Yasong Lu, Ornrat Lohitnavy, et al.. (2008). A Possible Role of Multidrug Resistance–Associated Protein 2 (Mrp2) in Hepatic Excretion of PCB126, an Environmental Contaminant: PBPK/PD Modeling. Toxicological Sciences. 104(1). 27–39. 22 indexed citations
17.
Lu, Yasong, Manupat Lohitnavy, Micaela B. Reddy, et al.. (2007). Quantitative analysis of liver GST-P foci promoted by a chemical mixture of hexachlorobenzene and PCB 126: implication of size-dependent cellular growth kinetics. Archives of Toxicology. 82(2). 103–116. 3 indexed citations
18.
Lu, Yasong, Manupat Lohitnavy, Micaela B. Reddy, et al.. (2006). An Updated Physiologically Based Pharmacokinetic Model for Hexachlorobenzene: Incorporation of Pathophysiological States following Partial Hepatectomy and Hexachlorobenzene Treatment. Toxicological Sciences. 91(1). 29–41. 14 indexed citations
19.
Lu, Yasong. (2006). Introduction to Physiologically Based Pharmacokinetic Model Construction:An Example of 1,1,1-Trichloroethane. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paola Puccini Breakdown of academic impact, for papers by Yaomin Du Breakdown of academic impact, for papers by Yukiyoshi Fujita Breakdown of academic impact, for papers by Hannah Lu Breakdown of academic impact, for papers by Kirk Bertelsen Breakdown of academic impact, for papers by Tsu‐Han Lin Breakdown of academic impact, for papers by Lisette Binkhorst Breakdown of academic impact, for papers by Sheng Ma Breakdown of academic impact, for papers by E Péquignot
Rankless by CCL
2026